144 0001098972 XXXXXXXX LIVE 0001840229 MiNK Therapeutics, Inc 001-40908 149 Fifth Avenue Suite 500 New York NY 10010 212-994-8250 Agenus Inc. Owner Common Stock B. Riley Financial

11000 Santa Monica Blvd, Suite 800, Los Angeles, CA 90025

786750 12572265.00 3966392 08/29/2025 INKT Common Stock 07/05/2017 These shares were acquired in an original issuance from the issuer, which was incorporated as a wholly owned subsidiary of Agenus Inc. MiNK Therapeutics, Inc. N 1948100 07/05/2017 These shares were acquired in exchange for Agenus Inc.'s initial capital contribution. Y EXPLANATION OF RESPONSES: 1. Agenus has no current intention to sell shares at prevailing market prices but seeks to preserve flexibility should market conditions change. The filing of this form does not represent an immediate sale plan. 2. Fair market value, of shares that may be sold, estimate based on the closing price of the Issuer's common stock on 8/27/2025 at $15.98. 3. In the event any sales of shares are made they must be completed within 90 days of the date of this filing. 4. These shares were acquired in an original issuance from the issuer, which was incorporated as a wholly owned subsidiary of Agenus Inc. 5. These shares were acquired in exchange for Agenus Inc.'s initial capital contribution. 08/29/2025 /s/ Garo Armen